Company intelligence / Profile preview

Chengdu Huahao Zhongtian Pharmaceutical

Chengdu, Sichuan, Chinabiostar-pharm.com ↗

Ownership: Private
Development stage: Other

Overview

Huahao Zhongtian’s lead product Utetron injection was approved in China in 2021 for recurrent or advanced metastatic breast cancer. It was included on the National Medical Insurance Drug List in March 2023. Utetron is a novel microtubule inhibitor developed via synthetic biology and represents the only new molecular structure of its class approved globally over the past decade. The company has additional pipeline assets including eutidron capsules/nanoparticles/antibody conjugates and several preclinical candidates targeting various oncology pathways.

Therapeutic areas: Oncology
Modalities: Small moleculeAntibody-drug conjugateNanoparticleAntibody
Industry: Biotech

Partnerships

Baiyang Zhihe (market promotion agreement)Luye Pharmaceutical

Beyond the preview

Go deeper on Chengdu Huahao Zhongtian Pharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chengdu Huahao Zhongtian Pharmaceutical.